ARMP - Armata Pharmaceuticals, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
4.1500
+0.1000 (+2.47%)
At close: 3:09PM EDT
Stock chart is not supported by your current browser
Previous Close4.0500
Open0.0000
Bid0.0000 x 1400
Ask4.0800 x 1400
Day's Range4.0500 - 4.0786
52 Week Range2.1000 - 19.1800
Volume3,201
Avg. Volume18,135
Market Cap41.328M
Beta (3Y Monthly)3.04
PE Ratio (TTM)N/A
EPS (TTM)-0.1390
Earnings DateNov 6, 2019 - Nov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Trade prices are not sourced from all markets
  • Armata Pharmaceuticals to Participate in the Ladenburg Thalmann 2019 Healthcare Conference
    PR Newswire

    Armata Pharmaceuticals to Participate in the Ladenburg Thalmann 2019 Healthcare Conference

    MARINA DEL REY, Calif. , Sept. 19, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics ...

  • Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa
    PR Newswire

    Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa

    MARINA DEL REY, Calif., Sept. 12, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (the "Company" or "Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the Company has developed a new synthetic phage candidate targeting the pathogen Pseudomonas aeruginosa (also referred to herein as "Pseudomonas" or "P. aeruginosa") to treat serious respiratory infections, with an emphasis on cystic fibrosis patients. The candidate, known as AP-PA02, is being developed as a replacement for AP-PA01, which was recently featured in the peer-reviewed journal Infection following the successful treatment of a multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient.

  • Armata Pharmaceuticals Announces Second Quarter Results and Provides Corporate and Clinical Update
    PR Newswire

    Armata Pharmaceuticals Announces Second Quarter Results and Provides Corporate and Clinical Update

    MARINA DEL REY, Calif. , Aug. 14, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused ...

  • How Much Of Armata Pharmaceuticals, Inc. (NYSEMKT:ARMP) Do Institutions Own?
    Simply Wall St.

    How Much Of Armata Pharmaceuticals, Inc. (NYSEMKT:ARMP) Do Institutions Own?

    The big shareholder groups in Armata Pharmaceuticals, Inc. (NYSEMKT:ARMP) have power over the company. Institutions...

  • Armata Pharmaceuticals to Provide Corporate Update at the 39th Annual Canaccord Genuity Growth Conference
    PR Newswire

    Armata Pharmaceuticals to Provide Corporate Update at the 39th Annual Canaccord Genuity Growth Conference

    MARINA DEL REY, Calif. , Aug. 1, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics ...

  • Armata Pharmaceuticals to Host Key Opinion Leader Meeting on Bacteriophage-Based Therapeutics on June 26 in New York
    PR Newswire

    Armata Pharmaceuticals to Host Key Opinion Leader Meeting on Bacteriophage-Based Therapeutics on June 26 in New York

    MARINA DEL REY, Calif., June 18, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it will host a Key Opinion Leader (KOL) meeting on phage-based therapeutics for the treatment of antimicrobial-resistant infections on June 26 from 12:00 – 1:30 PM EDT in New York City. The event will feature a presentation by Robert Schooley, MD, from the University of California-San Diego, who will discuss the rapidly growing antibiotic resistance crisis and the urgent need for the development of new antibiotic alternatives. Armata's management team will also provide an overview of the company's phage-based product candidates aimed to address areas of significant unmet clinical need by targeting key antibiotic-resistant bacteria.

  • Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with New Patent Allowances in Europe and Canada
    PR Newswire

    Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with New Patent Allowances in Europe and Canada

    MARINA DEL REY, Calif., June 3, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company continues to strengthen its intellectual property portfolio with the allowance of two patents by the European Patent Office and one allowance by the Canadian Intellectual Property Office.

  • Armata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient
    PR Newswire

    Armata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient

    MARINA DEL REY, Calif, May 28, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the publication of a case study involving a cystic fibrosis patient who was successfully treated for a multidrug-resistant Pseudomonas aeruginosa infection with the Company's natural phage product, AP-PA01. The paper, entitled "Successful adjunctive use of bacteriophage therapy for treatment of multidrug‑resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient," appears in the peer-reviewed journal Infection.